Loading...
News 2018-04-27T13:47:37+00:00

News

Number Title Author Date
23
Alteogen's Kadcyla biobetter gains edge in gastric cancer with FDA orphan designation
alteogen | 2018.08.17 | Votes 0 | Views 9
alteogen 2018.08.17
22
Alteogen Gets FDA Approval for Orphan Drug Designation with an Antibody-Drug Conjugate for Gastric Cancer
alteogen | 2018.08.07 | Votes 0 | Views 42
alteogen 2018.08.07
21
Alteogen develops antibody transferring IV to SC injection
alteogen | 2018.07.30 | Votes 0 | Views 41
alteogen 2018.07.30
20
Alteogen, Lynkogen targeting large NASH, diabetes markets in cross-royalty collaboration
alteogen | 2018.07.11 | Votes 0 | Views 36
alteogen 2018.07.11
19
Alteogen and Lynkogen Enter into an Exclusive Option Agreement
alteogen | 2018.07.04 | Votes 0 | Views 46
alteogen 2018.07.04
18
18 January 2018 Bio & Medicine Alteogen to seek US approval for clinical trials of Eylea biosimilar
alteogen | 2018.05.28 | Votes 0 | Views 67
alteogen 2018.05.28
17
23 Aug. 2017 Alteogen set to start phase I trial of ADC product in Korea
alteogen | 2018.05.28 | Votes 0 | Views 33
alteogen 2018.05.28
16
26 APR 2017 Alteogen partners with Cristalia to develop long-acting growth hormone
alteogen | 2018.05.28 | Votes 0 | Views 33
alteogen 2018.05.28
15
20 APR 2017 Alteogen to enter late-stage study of Herceptin biosimilar
alteogen | 2018.05.28 | Votes 0 | Views 26
alteogen 2018.05.28
14
29 MAR 2017 Korean firm to transfer biosimilar tech to Chinese partner
alteogen | 2018.05.28 | Votes 0 | Views 29
alteogen 2018.05.28